Investor Presentaiton
Breast cancer
products
3000+
hospitals
600+
Commercialization
team
Type
In-licensing Focus: Leverage BD to Expand Portfolio into Different Sub-types
of Breast Cancer
2L/2L+
1L
Perioperative
period
HER2+
HR+/
HER2-
•
注射用曲妥珠单抗
汉曲优
HLX11
Pertuzumab
Lasofoxifene
(HLX78)
•
Lasofoxifene (HLX78)
ESR1mut BC (2L+)
• HR+/HER2- (2L+) BC
Lasofoxifene (small molecule SERM*):
Lasofoxifene has tissue selectivity to the biological
activities of estrogen receptor (ER); ER shows
inhibitory activity in breast cancer cells while it can
activate bone tissue cells
Lasofoxifene has positive data from two phase II
clinical trials for ESR1-mutated breast cancer; PFS
reached 13.9 months in combination with
Abemaciclib (Eli Lilly's CDK4/6 inhibitor) (historical
PFS was ~5 months for Fulvestrant + Abemaciclib)
Lasofoxifene has less side effects such as
decreased bone density and menopause symptoms
compared with SERDS
In-licensing deal snapshot:
•
Henlius obtained exclusive rights to Lasofoxifene for
breast cancer treatment in China. Sermonix will
receive up to US$58M milestone payment in addition
to upfront payment and royalties
Henlius will join in Sermonix's MRCT phase III for at
least two indications in China, leveraging Henlius'
advantages in clinical operations
• With Henlius' efficient clinical execution and patient
enrollment speed, clinical trial of Lasofoxifene is
expected to be accelerated in China
*SERM: selective ER modulator; SERD: selective ER degraders
19
O 2024 Henlius.
2 HenliusView entire presentation